Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — Investor Presentation (May 2025)
25 slides from Jade Biosciences's investor presentation, May 14, 2025
Slide 1: Company Overview
May 2025 Company Overview NASDAQ: JBIO Exhibit 99.4
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation
Slide 3: Advancing potentially best-in-class therapies for autoimmune diseases
Notes: Jade has entered into an exclusive JADE101 license agreement with Paragon Therapeutics. Jade holds an exclusive option to license JADE201 and JADE-003 from Paragon. Jade has not yet entered into a license agreement with respect to JADE201 or JADE-003. MOA – mechanism of action; FIH – First-In
Slide 4: JADE101: a potentially best-in-class anti-APRIL mAb for IgAN
JADE101: a potentially best-in-class anti-APRIL mAb for IgAN
Slide 5: Jade is developing a potentially best-in-class anti-APRIL mAb
HV – healthy volunteer, mAb – monoclonal antibody, PoC – proof of concept Jade is developing a potentially best-in-class anti-APRIL mAb Estimated $10B+ branded market Current treatments do not adequately address the need for long-term disease-modifying therapy in a typically young IgAN patient popul
Slide 6: IgAN patient population and potential $10B+ market
*Per KDIGO guidelines, treatment should be initiated in all cases where patients have proteinuria ≥0.5 g/day. Notes: U.S. prevalence estimate from FDA; EU prevalence estimate from EMA; Japan / China prevalence estimates from a Novartis presentation. Estimated pricing of ~$120K-$150K per year based o
Slide 7: Proposed KDIGO guideline updates support frontline anti-APRIL potential
Expanding Patient Population Kidney biopsy recommended in all adults with proteinuria ≥0.5 g/d where IgAN is a possible diagnosis Recommends additional treatment should be initiated in all cases where patients have proteinuria ≥0.5 g/d Lower Proteinuria Targets Establishes new treatment goal: protei
Slide 8: Reducing pathogenic IgA production by plasma cells is potentially disease-modifying
APRIL dependency HSC Pro B cell Large pre-B cell Small pre-B cell Immature B cell Mature Naïve B cell Memory B cell Plasma cell Bone marrow Mucosa Mucosa & bone marrow CD20 expression BAFF dependency *Gradient indicates level of receptor expression Sources: 2024 Cheung (Front Nephrol); 2023 Mathur (
Slide 9: Selectively targeting APRIL avoids added immunosuppression of BAFF inhibition
Selectively targeting APRIL potentially provides disease modification without added immunosuppression of BAFF inhibition Sources: 2024 Cheung (Front Nephrol); Chinook 2022 CKD3 Presentation; 2004 Castigli (PNAS); 2001 Schiemann (Science) GWAS - Genome-Wide Association Studies, KO – knockout APRIL BA
Slide 10: APRIL inhibition drives TACI-Fc efficacy in IgAN
Reductions in proteinuria and IgA in IgAN clinical studies indicate APRIL inhibition is the driving force behind TACI-Fc efficacy Notes: Cross-trial comparisons are inherently limited and presented for hypothesis-generating purposes only. Data digitized from graphs where publications did not provide
Slide 11: Comparison of anti-APRIL and TACI-Fc programs in Phase 3
Sibeprenlimab Zigakibart Atacicept Povetacicept MoA anti-APRIL anti-APRIL TACI-Fc Engineered TACI-Fc Status P3 P3 P3 P3 Δ from baseline in critical disease markers (W36 timepoint*) N=79 (4/8 mg/kg pooled) N=35 (600 mg) N=32 (150 mg) N=9 (80 mg) GFR stabilization ✓ (12 months) ✓ (18 months) ✓ (24 mon
Slide 12: BAFF inhibition may cause long-term B cell depletion
Sources: 2022 Struemper (Lupus Sci Med); Barratt ASN 2024 BAFF inhibition is accompanied by the potential for significant long-term B cell depletion Long-term BAFF inhibition significantly depletes all B cell populations… … whereas chronic APRIL inhibition does not impact circulating lymphocytes 109
Slide 13: Deeper APRIL suppression drives superior clinical efficacy
Highest rates of clinical remission (proteinuria <0.3 g/day) for sibeprenlimab was accompanied by the deepest levels of APRIL suppression. Safety profile consistent across dose levels, with no increase in overall infections. Potential for anti-APRILs with higher affinity and increased systemic expos
Slide 14: Sibeprenlimab is potentially under-dosed in Phase 3
Sibeprenlimab dosed as a single 400mg SC injection Q4W in ongoing global Phase 3 VISIONARY trial. 400 mg SC Q4W equates to ~3.5 mg/kg IV for average IgAN patient (2.5-6 mg/kg). Estimated Phase 3 equivalent dose range demonstrated lower efficacy on key UPCR endpoints in Phase 2 ENVISION trial. ~50% o
Slide 15: Potentially best-in-class profile of JADE101
Potentially best-in-class profile of JADE101 Potentially best-in-class efficacy APRIL inhibitors demonstrate greater proteinuria reduction and increased clinical remission rates with higher exposures and more complete APRIL suppression Infrequent Q8W+ dosing Avoids unnecessary immunosuppression Sele
Slide 16: Potentially best-in-class properties of JADE101
Notes; Paragon has filed provisional patent applications covering the subject matter of JADE101, which we have exclusively licensed from Paragon. No head-to-head clinical trials have been conducted between JADE101 and the referenced drug candidates. Cross-trial comparisons are inherently limited and
Slide 17: JADE101 has femtomolar affinity and slow off-rate
Source: Internal data; Benchmarks manufactured based on publicly available sequences. Atacicept APRIL KD 672 pM (Vera internal data). IgA EC50 estimates calculated using compartmental PK models linked to indirect response models to describe IgA kinetics built using published PK and IgA concentration
Slide 18: JADE101 half-life and IgA reduction in NHPs
>3X increased half-life compared to sibeprenlimab in NHPs coupled with successful mitigation of TMDD … … which is accompanied by deep and prolonged IgA reduction in NHPs following a single, saturating dose PHARMACOKINETICS PHARMACODYNAMICS JADE101 (30 mpk) t1/2 ~ 27 days Sibeprenlimab (30 mpk) t1/2
Slide 19: Anticipated 1H26 HV data positions JADE101 for accelerated development
Anticipated 1H26 HV data potentially positions JADE101 for accelerated development MOA Program IND Enabling Phase 1 Initiation Interim Healthy Volunteer Data Potential Indications anti-APRIL JADE101 Ongoing 2H 2025 1H 2026 IgAN Anti-APRIL MOA provides biomarker rich data predictive of clinical effic
Slide 20: Biomarker-rich HV data supports accelerated clinical development
Notes: Sibeprenlimab IgAN IgA reductions (LHS) are average of 4 mg/kg and 8 mg/kg cohorts (HV data is from 6 mg/kg cohort); the two cohorts saw effectively equivalent IgA reduction at W4 and W8. Zigakibart UPCR data is at 52W. Atacicept IgAN W8 is average of W4 and W12 datapoints. Trend lines are be
Slide 21: Pipeline beyond JADE101
Pipeline beyond JADE101
Slide 22: Additional Jade programs in high-value autoimmune indications
Additional Jade programs expected to focus on best-in-class product profiles in high-value autoimmune indications Autoimmune indications with significant market opportunity Potentially best-in-class and best-in-indication product profile Potential rapid path to clinical PoC Limited competition expec
Slide 23: Advancing potentially best-in-class therapies for autoimmune diseases
Notes: Jade has entered into an exclusive JADE101 license agreement with Paragon Therapeutics. Jade holds an exclusive option to license JADE201 and JADE-003 from Paragon. Jade has not yet entered into a license agreement with respect to JADE201 or JADE-003. MOA – mechanism of action; FIH – First-In
Slide 24: Capitalization following close of merger with Aerovate
Capitalization following close of merger with Aerovate Number of Shares Shares outstanding 32,235,926 Preferred stock (as converted to common stock) 12,622,000 Pre-funded warrants 7,766,247 Notes: Number of shares are on an as-converted basis and following the 1:35 reverse stock split effected in co
Slide 25: Thank you
www.JadeBiosciences.com | info@jadebiosciences.com Thank you NASDAQ: JBIO